Webinar on Infex’s Phase II lead respiratory drug, RESP-X

On Jan 31st, Infex Therapeutics held a live webinar, to update on progress with our lead Phase II asset, RESP-X.

Infex Therapeutics logo

Infex to present webinar on lead Phase II respiratory drug RESP-X

RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the frequency of debilitating exacerbations in respiratory…

Approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa

RESP-X continues to exhibit strong safety and tolerability profile

Clinical candidate nominated for COV-X programme

COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral candidate

Podcast: Will A ‘Netflix’ Model Solve Antibiotic Reimbursement Challenges And Spur R&D?

Infex CEO Peter Jackson discusses the state of antimicrobial resistance in the UK, and globally. He highlights the potential of a new…

Infex strengthens Board with appointment of Professor Colm Leonard as Non-Executive Director

Infex Therapeutics is pleased to announce the appointment of Professor Colm Leonard as a Non-Executive Director of Infex with immediate…

Antimicrobial discovery and drug development – RSC Podcast

How do we develop drugs like antibiotics? How long does it take for such a drug to go from its inception in a research lab to use in a…

Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation

This designation gives MET-X an accelerated U.S. regulatory pathway and an additional five-years of market exclusivity upon approval.